कंपनी का अवलोकन
Myriad Genetics, Inc. operates as a specialized entity within the healthcare sector, specifically focusing on diagnostics and research where it develops and provides molecular diagnostic tests for oncology, women's health, and pharmacogenomics. The company offers a suite of services including the MyRisk Hereditary Cancer test, which utilizes DNA sequencing to identify hereditary cancers, alongside other precision medicine solutions designed to guide clinical decision-making. In terms of scale, the company maintains a market capitalization of $415.18M and employs approximately 2,700 individuals across its operations. These financial dimensions indicate that Myriad Genetics functions as a mid-cap enterprise with a significant operational footprint, yet the relatively modest market cap suggests it trades with a valuation profile distinct from larger pharmaceutical peers, reflecting its specific niche in genetic testing rather than broad-based drug manufacturing or broad consumer healthcare.
वित्तीय स्वास्थ्य
The company reported total revenue of $557.00M over the trailing twelve months, yet simultaneously recorded a net income loss of $-230,000,000 and an EBITDA of $-111,900,000. The substantial disparity between the positive revenue figure and the negative net income reveals a heavy cost structure, likely driven by high research and development expenditures or litigation-related charges that consume a significant portion of top-line earnings before reaching the bottom line. Free cash flow stands at $-46,062,500, indicating that the company is currently burning cash, which limits immediate financial flexibility for capital expenditures or aggressive debt reduction without external financing. Analyzing the profitability metrics, the gross margin sits at 68.1%, suggesting that the cost of goods sold is well-controlled relative to revenue, whereas the operating margin of -21.4% and profit margin of -41.3% demonstrate that operating expenses and other costs are severely eroding operational efficiency. Regarding liquidity and leverage, the company holds $150.70M in cash against $0 in debt, resulting in a debt-to-equity ratio of 32.84, which appears high numerically but reflects a capital structure free of interest obligations despite the negative equity implications of the losses. The current ratio is reported at 2.67, signaling that the company possesses more than double the current assets necessary to cover its short-term liabilities, thereby indicating robust short-term liquidity despite the earnings deficit. Furthermore, the return on equity is -23.5% and the return on assets is -7.6%, metrics that reveal that management has been ineffective at generating positive returns on the capital base during this period, a common characteristic for biotechnology firms in heavy investment phases or facing significant legal headwinds.
मूल्यांकन आकलन
Trailing earnings data is insufficient to calculate a standard P/E ratio, resulting in a TTM P/E of N/A, while the forward P/E is listed at 26.44, implying that the market is pricing in a significant turnaround or future earnings generation to justify the current share price. The price-to-book ratio is 1.13, which indicates that the market values the company at a slight premium over its tangible book value, suggesting that investors place some value on its intangible assets such as patents and proprietary testing technologies despite current losses. Alternative valuation metrics show a price-to-sales ratio of 0.75 and an EV/EBITDA of -2.36, suggesting that the stock is trading at a discount relative to sales, though the negative EV/EBITDA highlights the inability to cover operating costs from earnings at this moment. The stock has traded within a range defined by a 52-week high of $8.59 and a 52-week low of $3.76, meaning the current valuation fluctuates within a band where the price is currently positioned below the recent peak but above the yearly minimum. The beta value of 1.64 indicates that the stock exhibits price volatility that is significantly higher than the broader market, meaning price swings of 1% in the general market could translate to approximately 1.64% movement in MYGN shares, reflecting the high-risk nature of the diagnostics and research industry.
Growth & Income
Revenue growth year-over-year has contracted by -20.8%, while earnings growth is marked as N/A due to the negative net income position, indicating that top-line sales are declining and earnings are not expanding. Since earnings are negative, they are growing slower than revenue in a traditional sense, or rather, the company is unable to convert its sales into profit, implying ongoing structural challenges in cost management or revenue recognition. Regarding income distribution, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all retained earnings are theoretically available for reinvestment rather than distribution to shareholders. Consequently, the company reinvests its limited cash reserves and any future earnings into research, development, and operational scaling rather than providing a yield to investors. The overall growth and income profile for Myriad Genetics, Inc. is characterized by a lack of current profitability and revenue contraction, with no income generation for shareholders, positioning the asset as a pure speculative play on future potential rather than a current income or stable growth investment.